Abstract
Neurological and behavioral diseases caused by toxic metals, particularly aluminum, continue to pose a substantial issue for humans. Given the prevalence of aluminum in the Earth's crust, it is inevitable that humans worldwide will have contact with aluminum. The present study focuses on the synthesis and assessment of the therapeutic impact of cerium oxide nanoparticles (CeO(2) NPs) in rats that have been exposed to aluminum. The effect of CeO(2) nanoparticles on the functionality of enzymes and markers related to oxidative stress was assessed in the cerebral and hepatic tissues of rats subjected to aluminum exposure. The enzymes and markers assessed included catalase (CAT), cholinesterase (ChE), malondialdehyde (MDA), total antioxidant capacity (TAC), monoamine oxidase (MAO), reduced glutathione (GSH), and superoxide dismutase (SOD). Aluminum chloride was administered to the rats via subcutaneous injection at a daily dosage of 150 milligrams per kilogram for a duration of three weeks in order to generate oxidative stress. CeO(2) nanoparticles (NPs) were administered intraperitoneally at dosages of 5 and 10 mg/kg for a period of one week, with the initial administration occurring in the third week. The findings demonstrated that CeO(2) nanoparticles (NPs) were very successful in enhancing cognitive-behavioral patterns and increasing the activity of neurobiochemical enzymes in both liver and brain tissues. The findings indicated that CeO(2) NPs might serve as a viable therapeutic approach for addressing neurocognitive and neurobiochemical impairments caused by elevated aluminum levels in rats exposed to aluminum. However, further investigation is necessary to evaluate the therapeutic effectiveness of CeO(2) NPs on conditions caused by hazardous metal exposure.